

March 28, 2016



# OPKO Health Announces Executive Appointment

## **Ronald Trust, Ph.D., MBA, Appointed Vice President of Regulatory Affairs**

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:[OPK](#)) today announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.

Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.

"Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

## **About OPKO Health, Inc.**

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (in Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

*This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including all non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies, prospects, growth opportunities, and management. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements.*

*These factors include those described in our filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and, except as required by applicable law, we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.*

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160328005365/en/>

**OPKO Health, Inc.**

Tara Mackay, 305-575-4100

Investor Relations

or

**Media**

Rooney & Associates

Terry Rooney, 212-223-0689

[trooney@rooneyco.com](mailto:trooney@rooneyco.com)

or

Marion Janic, 212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors**

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.